Recruiting Studies
Advanced SearchData: ClinicalTrials.gov · Source of record for eligibility and locations
Top Cities for Diffuse Large B-Cell Lymphoma Clinical Trials
Diffuse Large B-Cell Lymphoma clinical trials are recruiting across 124 cities. Here are the cities with the most active studies:
Diffuse Large B-Cell Lymphoma Trial Phases
44 research organizations are sponsoring diffuse large b-cell lymphoma trials.
About Diffuse Large B-Cell Lymphoma
Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma, accounting for about 30% of cases. It is an aggressive lymphoma that grows rapidly. Treatment usually involves chemoimmunotherapy, with CAR-T cell therapy for relapsed cases.
Clinical trials are advancing new treatments for diffuse large b-cell lymphoma. Currently, 63 studies are recruiting a combined 14,050 participants across the United States. Research is being conducted by 44 organizations including OWKIN, Merck Sharp & Dohme LLC, Regeneron Pharmaceuticals and 41 others.
2026 Diffuse Large B-Cell Lymphoma Research Landscape
As of July 2026, the diffuse large b-cell lymphoma clinical trial landscape includes 63 actively recruiting studies across 124 cities in the United States. These studies are collectively seeking 14,050 participants, with an average enrollment target of 223 per study.
The research spans multiple phases of development: 41 studies are in PHASE2, 18 studies are in PHASE1, 5 studies are in PHASE3, 2 studies are in EARLY_PHASE1, 2 studies are in NA. The presence of Phase 3 trials indicates that some diffuse large b-cell lymphoma treatments are in late-stage testing and may be approaching regulatory review.
Research is being led by 44 different organizations, including OWKIN, Merck Sharp & Dohme LLC, Regeneron Pharmaceuticals, Kite, A Gilead Company, Lyell Immunopharma, Inc., and 39 others. The large number of sponsors reflects significant research interest and investment in diffuse large b-cell lymphoma treatment advancement.
Geographically, diffuse large b-cell lymphoma trials are most concentrated in Duarte, California (10 trials); Los Angeles, California (8 trials); Sacramento, California (7 trials); San Francisco, California (5 trials); Orange, California (5 trials) and 7 other cities.
Featured Diffuse Large B-Cell Lymphoma Studies
Highlighted recruiting studies for diffuse large b-cell lymphoma, selected by enrollment size and research scope.
A Non-interventional, International, Multicentre Clinical Research Study to Build the Largest Collection of Multimodal Data (Including Clinical Data, Imaging Data and Omics Data) in Oncology
Cancer is amongst the leading causes of disease-related morbidity and mortality. A major challenge in cancer treatment is the development of biology-informed, personalised treatment strategies. Recent advances in artificial intelligence (AI) and next-generation sequencing (NGS) technologies have shed further insights into disease biology and treatment pathways, thus identifying new, precision medi...
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
The purpose of this study is to evaluate if zilovertamab vedotin with standard treatment can help people live longer without the cancer growing or spreading than people who receive standard treatment alone.
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
This study is researching an experimental drug called odronextamab, referred to as study drug, when used in combination with chemotherapy. The study is focused on patients with Diffuse Large B-cell Lymphoma (DLBCL) that have not been treated before (called "previously untreated"). Patients with DLBCL that have come back after treatment (called "relapsed"), or have not responded to treatment (calle...
Frequently Asked Questions About Diffuse Large B-Cell Lymphoma Clinical Trials
Are there diffuse large b-cell lymphoma clinical trials near me?
Yes, there are 63 diffuse large b-cell lymphoma clinical trials currently recruiting across 124+ cities in the United States, including Duarte, California; Los Angeles, California; Sacramento, California. Browse the studies above to find one at a location convenient for you.
How do I join a diffuse large b-cell lymphoma clinical trial?
To join a diffuse large b-cell lymphoma clinical trial: 1) Browse the available studies on this page, 2) Click on a study that interests you, 3) Check the study locations to find a site near you, 4) Review the eligibility criteria, and 5) Contact the study site or complete the eligibility form. The process is free and you can withdraw at any time.
Are diffuse large b-cell lymphoma clinical trials free?
Yes, participation in diffuse large b-cell lymphoma clinical trials is free. Study-related treatments, medical tests, and doctor visits are provided at no cost to participants. Many studies also offer compensation for your time and travel expenses.
What types of diffuse large b-cell lymphoma treatments are being studied?
Current diffuse large b-cell lymphoma clinical trials are testing a range of approaches across PHASE2 (41 studies), PHASE1 (18 studies), PHASE3 (5 studies), EARLY_PHASE1 (2 studies), NA (2 studies). These include new drugs, combination therapies, medical devices, and other interventions sponsored by 44 research organizations.
Is it safe to participate in diffuse large b-cell lymphoma clinical trials?
Clinical trials are carefully regulated by the FDA and institutional review boards (IRBs). All trials must follow strict safety protocols, and participants receive close medical monitoring throughout the study. You can withdraw from a trial at any time without penalty.
Data updated July 15, 2026 from ClinicalTrials.gov
About This Data
Data: ClinicalTrials.gov · Source of record for eligibility and locations
Clinical trial information on this page is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health (NIH) and National Library of Medicine (NLM). Study data is refreshed every hour to ensure accuracy.
Medical Disclaimer: The information provided on this page is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before making decisions about clinical trial participation or changes to your treatment plan.
Page reviewed by the HelloStudys Research Team · Last updated July 15, 2026 · Data from ClinicalTrials.gov